FCGR3A and B-cell non-Hodgkin lymphoma: To investigate whether ADCC activity was influenced by an altered anti-MICA/B mAb-CD16 interaction, we tested the ability of an anti-CD20 mAb (rituximab, RTX) to mediate ADCC for Daudi target cells derived from a human B-cell lymphoma.